Literature DB >> 24976506

Poly(ADP-ribose): a signaling molecule in different paradigms of cell death.

Francesca Aredia1, Anna Ivana Scovassi2.   

Abstract

Poly(ADP-ribosylation) results from the conversion of NAD(+) into ADP-ribose and the following addition of ADP-ribose units to form polymers, further bound to acceptor proteins; once post-translationally ADP-ribosylated, proteins could change their function in basic processes. Poly(ADP-ribosylation) is activated under critical situations represented by DNA damage and cellular stress, and modulated in different paradigms of cell death. The hallmarks of the main death processes, i.e. apoptosis, parthanatos, necroptosis and autophagy, will be described, focusing on the role of poly(ADP-ribose) as a signaling molecule.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Autophagy; Necroptosis; PAR; PARP; Parthanatos

Mesh:

Substances:

Year:  2014        PMID: 24976506     DOI: 10.1016/j.bcp.2014.06.021

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  45 in total

1.  Suppressing PARylation by 2',5'-oligoadenylate synthetase 1 inhibits DNA damage-induced cell death.

Authors:  Anna A Kondratova; HyeonJoo Cheon; Beihua Dong; Elise G Holvey-Bates; Metis Hasipek; Irina Taran; Christina Gaughan; Babal K Jha; Robert H Silverman; George R Stark
Journal:  EMBO J       Date:  2020-04-23       Impact factor: 11.598

Review 2.  Cell death and autophagy in tuberculosis.

Authors:  Andrew H Moraco; Hardy Kornfeld
Journal:  Semin Immunol       Date:  2014-10-17       Impact factor: 11.130

Review 3.  CREBBP and p300 lysine acetyl transferases in the DNA damage response.

Authors:  Ilaria Dutto; Claudia Scalera; Ennio Prosperi
Journal:  Cell Mol Life Sci       Date:  2017-11-23       Impact factor: 9.261

4.  Ex Vivo Investigation of Bexarotene and Nicotinamide Function as a Protectıve Agent on Rat Synaptosomes Treated with Aβ(1-42).

Authors:  Ceyhan Hacioglu; Fatih Kar; Gungor Kanbak
Journal:  Neurochem Res       Date:  2021-01-11       Impact factor: 3.996

Review 5.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

Review 6.  The rise and fall of poly(ADP-ribose): An enzymatic perspective.

Authors:  John M Pascal; Tom Ellenberger
Journal:  DNA Repair (Amst)       Date:  2015-05-01

7.  CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.

Authors:  Tomoe Higuchi; Dallas B Flies; Nicole A Marjon; Gina Mantia-Smaldone; Lukas Ronner; Phyllis A Gimotty; Sarah F Adams
Journal:  Cancer Immunol Res       Date:  2015-07-02       Impact factor: 11.151

8.  Analysis from the perspective of cilia: the protective effect of PARP inhibitors on visual function during light-induced damage.

Authors:  Lin Che; Jing-Yao Song; Yan Lou; Guang-Yu Li
Journal:  Int Ophthalmol       Date:  2019-12-04       Impact factor: 2.031

9.  Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.

Authors:  Ryan Incrocci; Samira Hussain; Amanda Stone; Kathryn Bieging; Lauren A C Alt; Michael J Fay; Michelle Swanson-Mungerson
Journal:  Cell Immunol       Date:  2015-08-04       Impact factor: 4.868

10.  Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.

Authors:  Xianzhe Liu; Yan Gao; Jacson Shen; Wen Yang; Edwin Choy; Henry Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Mol Cancer Ther       Date:  2016-05-20       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.